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Purpose: Alcohol is not used directly to the vascular lesion without mixing with the contrast agent
because alcohol itself cannot be seen on the fluoroscopy. Since we have used alcohol for the
venous malformations in the head and neck area, we realized that alcohol can be safely and effec-
tively used without using fluoroscopy. We present the method of direct sclerotherapy using
absolute alcohol without using fluoroscopy.
Materials and Methods: After obtaining and carefully analyzing direct puncture venogram, we used this
technique in 22 patients who underwent alcohol sclerotherapy. Because fluoroscopy was not used
during alcohol injection, the angiotable can be placed outside of C-arm so that alcohol was comfort-
ably injected without any obstacle around the patients. Venogram can also be obtained between
the injections to detect whether there is any dangerous venous outflow drainage such as the superi-
or ophthalmic vein to the cavernous sinus. To control the venous outflow, local compression to the
draining vein was applied. The result and complication such as skin necrosis, infection, and nerve
injury were evaluated during mean follow-up period of 13 months (range, 1-63 months).
Results: The frequency of sclerotherapy was one in 16 and 2-5 in 6 patients. The volume of alcohol used
per treatment session ranged from 2 to 18 mL (mean, 8.5 mL). There was the minimum change in 1
(4.5%), moderately decreased lesion in 12 (54.5%), and markedly decreased lesion in 9 (41%)
patients. The patients did not reveal any complications during 12.9 months follow-up period.
Conclusion: Direct puncture alcohol sclerotherapy without using fluoroscopy can be a safe and effective
technique for treating venous malformation of the head and neck areas. In addition, the procedure
can be performed in the comfortable position because biplane fluoroscopy would not be necessary.
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http://dx.doi.org/10.5469/neuroint.2011.6.2.84Venous malformation (VM) is a common vascular
malformation, although they are not always evident at
birth, with 40% of cases found in the head and neck
region [1-3]. And it has been known as one of the
most difficult disease entities diagnostically and
therapeutically in the daily practice [4, 5].
The treatment of VMs presents a challenge to
interventional physicians. Percutaneous alcohol
sclerotherapy has been reported to be effective in the
primary treatment of venous malformations of the head
and neck region [5-8]. Alcohol is believed to have the
lowest rate of recurrence of all the sclerosants [7].
However, it is associated with potential clinically
important complications that were usually classified as
either local or systemic. Local complications include
any transient adverse effects, such as transient nerve
injuries, skin blistering, or skin necrosis. Systemic
complications include death, and permanent adverse
effects, such as cardiovascular or pulmonary events [4,
6, 7, 9]. Therefore, a total amount of alcohol that can be
given in a procedure should not exceed 1.0 mL/kg
body weight [4, 7, 10, 11]. The dose limitation is based
on the clinical experience of the interventional
physicians with respect to the procedure itself and the
postprocedural course [7]. However, systemic introduc-
tion of alcohol can be dangerous, regardless of dose
used, for large VM with rapid inflow and outflow of
the lesion. Thus, it is important to regulate flow factors
of VM to achieve alcohol sclerotherapy safely and
effectively.  
In conventional percutaneous slcerotherapy, manual
compression of the draining vein has been usually used
for flow reduction to avoid inadvertent distal migration
of sclerosant [12]. In contrast, we used pure absolute
alcohol without mixing contrast agent and fluoroscopic
guidance with manual compression to the VM itself.
We found that this method can be helpful to increase
sclerotic effect and to reduce the total amount of
alcohol and complications. We present our experience
and the outcome of percutaneous alcohol sclerotherapy
without using fluoroscopy for VM of the head and neck
region.  
MATERIALS AND METHODS
Patient Selection  
We obtained approval from the institutional review
board of our hospital for a review and utilization of
patient medical and imaging records. Written informed
consent for the procedure was obtained from all
patients and their families after a discussion about the
advantages and risks for the procedure.  
Patients were identified from the neurointerventional
database of our institution. From May 2007 to June
2009, a total of 22 consecutive patients with VMs of
the head and neck region were treated with absolute
alcohol sclerotherapy (12 female patients and 10 male
patients) in our department. The mean age was 30.3
years (age range, 3-67 years). The onset of the
symptoms or detection of the lesion varied from
childhood to adulthood. Nineteen of the lesions were
located on the face, including the lip, cheek,
submandibular, temporal, and periorbital areas. One of
the lesions was on the tongue, and 2 were located in the
neck. All patients had one or more symptoms and the
most common symptom was painless swelling (95.5%)
with the next common symptom being discoloration
(45.5%). Two had recurrent bleeding episodes from the
lesion.  
Eleven patients had a history of operations, and the
remaining 11 patients were treated by alcohol
sclerotherapy as the primary treatment technique and
then a patient out of 11 underwent surgical resection.  
Treatment Details  
Direct percutaneous alcohol sclerotherapy was
performed under intermittent fluoroscopic guidance
(Axiom Artis dBA system, Siemens AG, Medical
Solutions, Forchheim, Germany), sterile conditions,
and  general  anesthesia.  18-gauge  needle  (BD
Angiocath Plus, Becton Dikinson Korea, Seoul, Korea)
were directly inserted into the venous pouch of VM
until blood return was observed. Venography with
water-soluble iodinated contrast material confirmed
needle position within the VM and assessed venous
drainage. Appropriate venous pouch occlusion was
performed with manual compression, and contrast
material injection was repeated until no undesirable
outflow into normal vessels occurred. This step was
applied when the venous drainage was toward deep or
dangerous/intracranial structures such as the cavernous
sinus.  
Alcohol was then injected under visual control for
VMs without using fluoroscopic control. If required,
fluoroscopic guidance was used between the alcohol
injections to detect whether there is any dangerous
venous outflow drainage such as the superior
ophthalmic vein to the cavernous sinus. Up to 18cc of
alcohol was injected at each session. Absolute (99%)
alcohol was used during the procedure without mixing
with the contrast agent to render the mixture
radiopaque. The total volume and the volume of the
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ing to the size of the VM and the size of the vessels
being injected, with a maximum total dose of 1.0
mL/kg. The time over which the alcohol was adminis-
tered varied, depending on the complexity of the
procedure. Schematic drawing about the procedure
illustrated in Fig. 1.
The aim of treatment was symptom palliation and
size reduction. Thus, sclerotherapy sessions were
repeated until either the patient felt they could tolerate
residual symptoms or the physician was unable to
identify any further venous pouches to target with
treatment. Patients were observed after the procedure
for swelling, pain control, hematuria, and other compli-
cations.  
Evaluation of Clinical Data and Follow-up Results
Patients were initially followed up at our department
approximately 6-12 weeks after the procedure. This
time allowed resolution of swelling and changes
directly related to sclerotherapy and proper assessment
of the treatment results. Recommendations for repeat
sclerosis or clinical follow-up were based on this initial
assessment. Results of sclerotherapy were classified
with subjective clinical assessment, including interview
and examination. MR imaging follow-up was available
for 4 (18.2%) of 22 patients but was not included in the
evaluation of clinical results. An interventional neurora-
diologist (D.C.S.) performed the assessments. Both
lesion size and patient symptoms were assessed includ-
ing pain, degree of residual functional impairment, and
cosmetic deformity. Clinical follow-up after the last
treatment session was performed in all patients and
ranged from 1 to 63 months (mean, 13 months). Clinical
outcomes were classified as follows: (a) little or no
change; (b) moderate decrease in size and symptoms;
and (c) markedly decreased in size with clinical obliter-
ation. Complications included death, permanent
sequelae including skin necrosis, nerve palsy and
infection, requirement of major therapy including
infection, and prolonged hospitalization. Minor compli-
cations included any transient adverse effect.
RESULTS
During the 37 direct puncture alcohol sclerotherapy
(range, 1-5; mean, 1.7) in 22 patients, the amount of
alcohol ranged from 2 to 18 mL (mean, 8.5 mL) in a
single session. When maximum amounts of alcohol
were used, the total dose did not exceed 1.0 mL/kg of
body weight. No patient experienced alcohol toxicity.
Percutaneous alcohol sclerotherapy resulted in
improvement or resolution of symptoms in 21 (95.5%)
of 22 patients. The mean follow-up duration was 13
months (range, 1-63 months). With regard to the
clinical outcome of alcohol sclerotherapy, 9 of 22
patients (41%) were markedly decreased in size, 12
(54.5%) were moderately decreased, and 1 (4.5%) had
little change. A single session was performed in 16
patients (72.7%); multi-staged sclerotherapy was
required in 6 patients (27.3%).  
Two patients (9.1%) of 22 patients had minor compli-
cations including paraesthesia of the lesion, and
reversible ophthalmic venous thrombosis. However,
these complications recovered completely with time.
And there was no procedure-related mortality. The
patients’ clinical data, technical details, and clinical
outcomes are summarized in Table 1.
DISCUSSION
VMs are a congenital vascular malformation,
although they are not always evident at birth, with 40%
of cases found in the head and neck region. These
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Fig. 1. Schematic procedural diagram of the compression technique during alcohol injection. 
A. A needle tip is in the secured position in venous malformation of the subcutaneous area. 
B. Venogram is obtained during compression and subsequent alcohol injection is done in the same position. 
C. Additional compression is required if there is any dangerous venous drainage.lesions are “low-flow” vascular malformations that
consist of dysmorphic channels lined by flattened
endothelium and a thin basement membrane. They may
become clinically apparent at any time throughout the
lifespan, because they grow proportionately with age
and do not regress [1-3].  
Symptoms can have a wide range including pain,
swelling, bluish-purple discoloration, infection, or
bleeding. Functional impairment may be present,
depending on the size, location, hemodynamic effects,
and type of vessel involved. VM can be enlarged due to
dilated venous channels during the Valsalva maneuver
[13, 14].  
Diagnosis is usually based on clinical presentation,
with confirmation by MR imaging. VMs demonstrate
septated soft tissue lesion with high signal intensity on
T2-weighted images and phleboliths may be shown as
multiple round signal intensity voids on MR images.
Contrast administration results in a variable enhance-
ment pattern, ranging from attenuated enhancement
similar to that in adjacent veins to nonhomogeneous or
delayed enhancement [2, 14].  
Treatment of VMs is challenging but percutaneous
alcohol sclerotherapy is the most common therapeutic
option by means of direct lesional puncture. Among the
sclerosing agents, alcohol is one of the most effective
sclerosant which can induce denudation of endothe-
lium, intense inflammatory reaction, and thrombosis of
the VMs almost immediately [1, 5, 7].
In this study, we administrated absolute alcohol under
visual control, without using fluoroscopic guidance and
without mixing contrast agent. And we also used
manual compression of the VM itself for preventing
adverse embolic effect of alcohol and evaluating the
course of injected alcohol beyond the venous pouch
during the procedure. We found that this method can be
helpful to increase sclerotic effect and to reduce the
total amount of alcohol and complications for treating
VMs. Our results showed that moderate or markedly
decreased size of the lesion resulted in 21 (95.5%) of
22 patients overall; these findings appear to be similar
or higher rate than those in the previous studies [4, 11,
14]. Despite of only visual control during alcohol
injection without using fluoroscopic guidance, there
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Table 1. Clinical Data, Technical Details, and Clinical Outcomes in 22 Patients with Venous Malformations
Patient  Sex/
No.  Complication Clinical
Clinical 
No. Age




01 M/32 Submandibular  S 1 No No 07E
02 M/38 Neck S, P 4 No No 26 E
03 M/17 Cheek, lip S 4 No No 63 G
04 M/25 Tongue S, D, I1 No No 01E
05 F/54 Cheek S, I1 No No 26 E
06 F/3 Neck S, P 1 No No 08E
07 F/39 Periorbital  S, D 1 No ROVT 17 G
08 M/8 Lip S, D 3 No No 42 G
09 F/17 Lip S, I, D 1 No No 13 G
10 F/30 Cheek S, I, D 5 No No 13 G
11 M/24 Lip S, D 1 No No 07E
12 F/41 Cheek S 1 No No 07E
13 F/43 Temporal S 2 No No 23 NC
14 M/23 Cheek S 1 No No 06E
15 F/21 Cheek S 1 No No 06E
16 F/31 Lip S, I, D 1 No No 01G
17 M/45 Lip S, B 1 No No 01G
18 F/14 Submandibular  S 1 No No 01G
19 F/38 Lip S, I, D 1 No No 06G
20 M/29 Face S, I3 No No 09G
21 M/28 Lip S, D 1 No Pa 01G
22 F/67 Lip D, B 1 No No 01G
Abbreviations: S, swelling; P, pain; D, discoloration; I, increase in size; B, bleeding; Pa, paresthesia; NC, no change; G, good:
moderately decreased size; E, excellent: markedly decreased size; ROVT, reversible ophthalmic venous thrombosis. 88 Neurointervention 6, August 2011
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was no additional risk about an occurrence of compli-
cations. Our results showed that only two of 22 patients
had minor complications, and there was no procedure-
related mortality. Compared to previous reports [1, 4,
10, 11], total amount of alcohol for sclerosis of the
lesion could be markedly reduced by using this
technique. A decreased amount of alcohol may also
reduce local or systemic complications related to
alcohol toxicity. In addition, position of the operator
was comfortable because biplane fluoroscopy would
not be necessary. However, in case of venous malfor-
mation with rapid outflow drainage, the intermittent
fluoroscopic guidance should be performed to control
rapid flow during the entire procedure.  
Our study had several limitations. First, our study did
not include large number of patients. Further risk that
we could not detect can be identified. Therefore,
careful application of this technique by experts is
mandatory. Second, because there is no standard report
form for VMs, we used our own criteria to assess the
clinical outcome; this can make it difficult to compare
our results with those from other studies. Furthermore,
MR imaging follow-up was available for 4 patients,
and we did not include follow-up MR images in the
evaluation of clinical results. Follow-up MR imaging
can be helpful to provide more objective information
for evaluating clinical outcomes.  
In conclusion, direct puncture alcohol sclerotherapy
without fluoroscopy guidance can be a safe and
effective technique for treating VMs of the head and
neck areas.  
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